Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | EDNRA | P25101 | 2/20 | 0.45 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.41 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.41 |
| ▸ | EDNRB | P24530 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.37 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.36 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27481427 | 0.89 | ALDH1A1 (0.42) | ALDH1A1EDNRAAKR1C3AKR1C1EDNRB | |
| SCHEMBL8370418 | 0.85 | ALDH1A1 (0.48) | ALDH1A1EDNRAAKR1C3AKR1C1EDNRB | |
| SCHEMBL5970111 | 0.85 | SLC6A2 (0.46) | ALDH1A1EDNRAAKR1C3AKR1C1EDNRB | |
| SCHEMBL5969949 | 0.85 | SLC6A2 (0.46) | ALDH1A1EDNRAAKR1C3AKR1C1EDNRB | |
| SCHEMBL15335817 | 0.85 | NOTUM (0.43) | ALDH1A1EDNRAAKR1C3AKR1C1EDNRB | |
| SCHEMBL2470428 | 0.85 | SLC6A2 (0.46) | ALDH1A1EDNRAAKR1C3AKR1C1EDNRB | |
| SCHEMBL28373219 | 0.82 | ALDH1A1 (0.44) | ALDH1A1EDNRAAKR1C3AKR1C1MEN1 | |
| SCHEMBL29508339 | 0.82 | ALDH1A1 (0.44) | ALDH1A1EDNRAAKR1C3AKR1C1MEN1 | |
| SCHEMBL4960327 | 0.80 | ALDH1A1 (0.39) | ALDH1A1EDNRAAKR1C3AKR1C1EDNRB | |
| SCHEMBL10145348 | 0.80 | SLC6A2 (0.50) | TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 104 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10076888-B2 | Multi-layer materials and articles made therefrom and methods of making | SABIC GLOBAL TECHNOLOGIES B.V. (NL) | 2018-09-18 | — | — | US | claimed |
| US-20180117871-A1 | MULTI-LAYER MATERIALS AND ARTICLES MADE THEREFROM AND METHODS OF MAKING | SABIC GLOBAL TECHNOLOGIES B.V. (NL) | 2018-05-03 | — | — | US | claimed |
| CN-107548352-A | Multilayer material and the product being produced from it and manufacture method | 沙特基础工业全球技术有限公司 | 2018-01-05 | — | — | CN | claimed |
| EP-3164266-A1 | MULTI-LAYER MATERIALS AND ARTICLES MADE THEREFROM AND METHODS OF MAKING | SABIC Global Technologies B.V. (NL) | 2017-05-10 | — | — | EP | claimed |
| WO-2016174577-A1 | MULTI-LAYER MATERIALS AND ARTICLES MADE THEREFROM AND METHODS OF MAKING | SABIC GLOBAL TECHNOLOGIES B.V. (NL) | 2016-11-03 | — | — | WO | claimed |
| EP-1565421-B1 | A METHOD FOR PREPARING INDAN-1,3-DICARBOXYLIC ACID | PFIZER PROD INC (US) | 2008-07-23 | — | — | EP | claimed |
| US-7009073-B2 | Method for preparing indan-1,3-dicarboxylic acid | PFIZER INC (US) | 2006-03-07 | — | — | US | claimed |
| US-20050240057-A1 | Method for preparing indan-1,3-dicarboxylic acid | PFIZER INC | 2005-10-27 | — | — | US | claimed |
| EP-1565421-A1 | A METHOD FOR PREPARING INDAN-1,3-DICARBOXYLIC ACID | Pfizer Products Inc. (US) | 2005-08-24 | — | — | EP | claimed |
| WO-2004046077-A1 | A METHOD FOR PREPARING INDAN-1,3-DICARBOXYLIC ACID | PFIZER PRODUCTS INC. (US) | 2004-06-03 | — | — | WO | claimed |
| EP-3164266-B1 | MULTI-LAYER MATERIALS AND ARTICLES MADE THEREFROM AND METHODS OF MAKING | SABIC GLOBAL TECHNOLOGIES BV (NL) | 2019-05-29 | — | — | EP | disclosed |
| US-10076888-B2 | Multi-layer materials and articles made therefrom and methods of making | SABIC GLOBAL TECHNOLOGIES B.V. (NL) | 2018-09-18 | — | — | US | disclosed |
| EP-2333001-B1 | COMPOSITIONS OF POLYESTERS WITH A HIGH GLASS TRANSITION TEMPERATURE WHICH COMPRISE 2,2,4,4-TETRAMETHYL-1,3-CYCLOBUTANEDIOL AND CERTAIN THERMAL STABILIZERS AND ARTICLES THEREOF | EASTMAN CHEM CO (US) | 2018-07-25 | — | — | EP | disclosed |
| US-10017606-B2 | Polyester compositions containing cyclobutanediol having a certain combination of inherent viscosity and moderate glass transition temperature and articles made therefrom | EASTMAN CHEMICAL COMPANY (US) | 2018-07-10 | — | — | US | disclosed |
| US-20180117871-A1 | MULTI-LAYER MATERIALS AND ARTICLES MADE THEREFROM AND METHODS OF MAKING | SABIC GLOBAL TECHNOLOGIES B.V. (NL) | 2018-05-03 | — | — | US | disclosed |
| EP-1565421-A1 | A METHOD FOR PREPARING INDAN-1,3-DICARBOXYLIC ACID | Pfizer Products Inc. (US) | 2005-08-24 | — | — | EP | disclosed |
| EP-1565421-A1 | A METHOD FOR PREPARING INDAN-1,3-DICARBOXYLIC ACID | Pfizer Products Inc. (US) | 2005-08-24 | — | — | EP | disclosed |
| WO-2004046077-A8 | A METHOD FOR PREPARING INDAN-1,3-DICARBOXYLIC ACID | PFIZER PROD INC (US) | 2005-05-19 | — | — | WO | disclosed |
| WO-2004046077-A1 | A METHOD FOR PREPARING INDAN-1,3-DICARBOXYLIC ACID | PFIZER PRODUCTS INC. (US) | 2004-06-03 | — | — | WO | disclosed |
| WO-2004046077-A1 | A METHOD FOR PREPARING INDAN-1,3-DICARBOXYLIC ACID | PFIZER PRODUCTS INC. (US) | 2004-06-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050240057-A1 | Method for preparing indan-1,3-dicarboxylic acid | DDC, IMPDH1, IDO1 | ALDH1A1 223/4885EDNRA 2842/4885AKR1C3 1599/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.